Skip to main content
SpringerLink
Log in

Docetaxel Loaded Pomegranate Seed Oil Based Nanostructured Lipid Carriers: A Potential Alternative to Current Formulation

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The current work is focused on the development of docetaxel loaded pomegranate seed oil based lipid nanosystem. Docetaxel loaded pomegranate seed oil nanostructured lipid carriers (DTX-PSO-NLCs) were formulated by the melt emulsification method for parenteral delivery. The developed formulation was characterized in terms of their physicochemical parameters, solid-state characterization, in vitro drug release, in vitro cytotoxicity studies, and in vivo pharmacokinetics and biodistribution studies. Stability studies were carried out as per ICH guidelines Q1A. Melt emulsification method resulted in the formulation of stable DTX-PSO-NLCs with a particle size in the range of 150–180 nm and an entrapment efficiency of 63–65%. The in vitro release showed a slow and sustained release of the drug from the formulation compared to the marketed formulation (i.e., Daxotel®). The formulation was found to be stable for a period of 12 months at conditions of 4°C ± 2°C, 25°C ± 2°C/60% RH ± 5%RH, and 40°C ± 2°C/75% RH ± 5%RH. The developed nanosystem exhibited promising antitumor activity against various types of cancerous cell lines (i.e., MCF7, DU145, U87MG, and NCI-H460) relative to the marketed formulation. The pharmacokinetic evaluation revealed that DTX-PSO-NLCs had a better kinetic profile compared to the marketed formulation.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 – IARC. [Online] Available from: https://www.iarc.fr/featured-news/latest-global-cancer-data-cancer-burden-rises-to-18-1-million-new-cases-and-9-6-million-cancer-deaths-in-2018/ [Accessed: 15th May 2020].

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer J Clin. [Online] Wiley; 2020;70(1): 7–30. Available from: https://doi.org/10.3322/caac.21590.

  3. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. [Online] Lancet Oncology. Elsevier; 2005. p. 229–239. Available from: https://doi.org/10.1016/S1470-2045(05)70094-2.

  4. Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II Trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada clinical trials group. Investigational New Drugs. [Online] Springer New York LLC; 1996;14(2): 203–206. Available from: https://doi.org/10.1007/BF00210791.

  5. Li X, Wang D, Zhang J, Pan W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. 2009; 1485–1492. Available from: https://doi.org/10.1211/jpp/61.11.0007.

  6. Kharkar PB, Talkar SS, Patravale VB. An industrially viable technique for fabrication of docetaxel NLCs for oncotherapy. Int J Pharm. [online] Elsevier B.V.; 2020;577: 119082. Available from: https://doi.org/10.1016/j.ijpharm.2020.119082.

  7. Poovi G, Damodharan N. Lipid nanoparticles: a challenging approach for oral delivery of BCS class-II drugs. Future J Pharm Sciences. [Online] Springer Science and Business Media LLC; 2018;4(2): 191–205. Available from: https://doi.org/10.1016/j.fjps.2018.04.001.

  8. Ngo AN, Thomas D, Murowchick J, Ayon NJ, Jaiswal A, Youan BBC. Engineering fast dissolving sodium acetate mediated crystalline solid dispersion of docetaxel. Int J Pharm. [Online] Elsevier B.V.; 2018;545(1–2): 329–341. Available from: https://doi.org/10.1016/j.ijpharm.2018.04.045.

  9. Caban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. 2014.

    Google Scholar 

  10. Battaglia L, Ugazio E. Lipid nano-and microparticles: an overview of patent-related research. 2019; Available from: https://doi.org/10.1155/2019/2834941 [Accessed: 21st April 2020].

  11. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. [Online] Biomedicine and Pharmacotherapy. Elsevier Masson SAS; 2018. p. 598–613. Available from: https://doi.org/10.1016/j.biopha.2018.04.055 [Accessed: 23rd April 2020].

  12. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. [Online] 2002;242(1–2): 121–128. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12176234 [Accessed: 18th May 2018].

  13. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B: Biointerfaces. [Online] 2011;85(2): 262–269. Available from: https://doi.org/10.1016/j.colsurfb.2011.02.038 [Accessed: 22nd April 2020].

  14. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacology. [online] 2007;109(2): 177–206. Available from: https://doi.org/10.1016/j.jep.2006.09.006.

  15. Syed DN, Afaq F, Mukhtar H. Pomegranate derived products for cancer chemoprevention. Semin Cancer Biol. [Online] 2007;17(5): 377–385. Available from: https://doi.org/10.1016/j.semcancer.2007.05.004.

  16. Khoddami A, Man YBC, Roberts TH. Physico-chemical properties and fatty acid profile of seed oils from pomegranate ( Punica granatum L.) extracted by cold pressing. Eur J Lipid Sci Tech. [Online] Wiley-VCH Verlag; 2014;116(5): 553–562. Available from: https://doi.org/10.1002/ejlt.201300416 [Accessed: 12th July 2020].

  17. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B: Biointerfaces. [Online] 2007;60(2): 174–179. Available from: https://doi.org/10.1016/j.colsurfb.2007.06.011.

  18. Kharkar PB, Talkar SS, Patravale VB. A rapid and sensitive bio analytical rp-hplc method for detection of docetaxel: development and validation. Indian J Pharm Educ Res. [Online] 2017;51(4): S729–S734. Available from: https://doi.org/10.5530/ijper.51.4s.105 [Accessed: 12th January 2019].

  19. Protocol Guide: MTT assay for cell viability and proliferation | Sigma-Aldrich. [Online] Available from: https://www.sigmaaldrich.com/technical-documents/protocols/biology/roche/cell-proliferation-kit-i-mtt.html [Accessed: 25th April 2020].

  20. Rakshit KD, Darukeshwara J, Rathina Raj K, Narasimhamurthy K, Saibaba P, Bhagya S. Toxicity studies of detoxified Jatropha meal (Jatropha curcas) in rats. Food Chem Toxicol. [Online] 2008;46(12): 3621–3625. Available from: https://doi.org/10.1016/j.fct.2008.09.010 [Accessed: 25th April 2020].

  21. Liang X, Zhang J, Zhu Y, Lu Y, Zhou X, Wang Z, et al. Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clin Transl Oncol. [Online] 2013;15(4): 331–334. Available from: https://doi.org/10.1007/s12094-012-0936-6 [Accessed: 24th April 2020].

  22. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. [Online] 2018;10(2): 1–17. Available from: https://doi.org/10.3390/pharmaceutics10020057.

  23. Shah N V., Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. [Online] Elsevier; 2016;7(3): 423–434. Available from: https://doi.org/10.1016/j.jare.2016.03.002.

  24. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. [Online] 2012;47(1): 139–151. Available from: https://doi.org/10.1016/j.ejps.2012.05.010 [Accessed: 20th September 2020].

  25. Davis PJ, Bosenberg A, Davidson A, Jimenez N, Kharasch E, Lynn AM, et al. Pharmacology of pediatric anesthesia. Smith’s Anesthesia Infant Child. [Online] Elsevier Inc.; 2011. p. 179–261. Available from: https://doi.org/10.1016/B978-0-323-06612-9.00007-9 [Accessed: 23rd April 2020].

  26. Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs. [Online] 1996;14(2): 147–151. Available from: https://doi.org/10.1007/bf00210785 [Accessed: 23rd April 2020].

Download references

Acknowledgments

We are also thankful to Amit Pomeg-Tech and (Gujrat, India) and Dr. Reddy’s Laboratory (Hyderabad, India) for providing Pomegranate Seed Oil and Docetaxel anhydrous, respectively.

Funding

The author acknowledges the UGC-NET JRF (Ref no. 18-12/2011(ii) EU-V) for funding the research.

Author information

Author notes

  1. Swapnil S. Talkar and Prachi B. Kharkar contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N. P. Marg, Matunga, Mumbai, Maharashtra, 400 019, India

    Swapnil S. Talkar, Prachi B. Kharkar & Vandana B. Patravale

Authors
  1. Swapnil S. Talkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prachi B. Kharkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vandana B. Patravale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vandana B. Patravale.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 780 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Talkar, S.S., Kharkar, P.B. & Patravale, V.B. Docetaxel Loaded Pomegranate Seed Oil Based Nanostructured Lipid Carriers: A Potential Alternative to Current Formulation. AAPS PharmSciTech 21, 295 (2020). https://doi.org/10.1208/s12249-020-01839-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-020-01839-1

Key Words

Search

Navigation